Dr lalchandani labs Limited has announced an extension of its ongoing rights issue closing date following a board meeting held on February 16, 2026. The company has now published newspaper advertisements on February 17, 2026, formally notifying stakeholders about the extension.

Rights Issue Extension Details

The company's board of directors approved the extension of the rights issue closing date during their meeting on February 16, 2026. The rights issue, which commenced on February 04, 2026, was initially scheduled to conclude on February 20, 2026, but has now been extended by one week to February 27, 2026.

Alongside the main issue extension, the company has also extended the deadline for on-market trading in rights entitlements. The trading window, originally set to close on February 17, 2026, has been extended to Tuesday, February 24, 2026.

Newspaper Publication and Regulatory Compliance

On February 17, 2026, Dr Lalchandani Labs Limited published newspaper advertisements in Financial Express (English - All Edition) and Jansatta (Hindi - All editions) to formally communicate the extension details to all stakeholders. The publication was submitted to BSE Limited with scrip code 541299, signed by Managing Director Arjan Lal Chandani (DIN: 07014579).

Revised Rights Issue Timeline

The company has provided a comprehensive revised schedule for the rights issue process:

Board Meeting and Documentation

The board meeting commenced at 01.30 p.m. and concluded at 02:00 p.m. on February 16, 2026. The company has clarified that except for the extension of the issue closing date and consequential changes in the post-issue timeline, there are no other modifications to the Letter of Offer (LOF), Composite Application Form (CAF), or other issue-related documents, all dated January 20, 2026.

Rationale for Extension

The extension has been granted specifically to facilitate better participation from eligible shareholders and to provide them with adequate time to subscribe to the rights issue. This strategic decision demonstrates the company's commitment to ensuring maximum shareholder participation in the capital raising exercise.

The announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the information is also available on the company's website at lalchandanipathlab.com.

Dr Lalchandani Labs Limited has completed the dispatch of rights issue material for its upcoming equity offering, as announced in a regulatory filing dated January 31, 2026. The company has notified BSE Limited about the newspaper publication intimation under relevant SEBI regulations regarding the completion of rights issue dispatch.

Rights Issue Details

The company is offering up to 43,32,000 fully paid-up equity shares of face value ₹10 each for cash at par, at a price of ₹10 per rights equity share. The total issue size aggregates up to ₹433.20 lakhs, assuming full subscription.

Issue Timeline

The rights issue follows a structured timeline for eligible equity shareholders to participate in the offering.

Application Process and Requirements

All shareholders desiring to make an application in this issue are mandatorily required to use the Application Supported by Blocked Amount (ASBA) process in accordance with SEBI regulations. The credit of rights entitlements and allotment of rights equity shares shall be made in dematerialised form only.

The company has established a separate demat suspense escrow account named "DR LALCHANDANI LABS LIMITED RIGHTS ISSUE SUSPENSE ESCROW DEMAT ACCOUNT" for specific cases where rights entitlements cannot be directly credited to eligible shareholders' accounts.

Eligible Shareholders and Restrictions

The rights issue is available to eligible equity shareholders as on the record date of January 27, 2026. The company has dispatched issue material through email to shareholders who provided valid email addresses, while physical dispatch has been completed for those without email addresses on a reasonable effort basis.

Eligible equity shareholders who do not receive application forms may apply on plain paper under the ASBA process, provided they include all required details as specified in the regulations. However, shareholders making applications on plain paper will not be entitled to renounce their rights entitlements.

Regulatory Compliance

The announcement was made in compliance with Regulation 84(1) of SEBI ICDR Regulations and Regulation 30 of SEBI LODR Regulations. The newspaper advertisements were published in Financial Express (English - All Edition) and Jansatta (Hindi - All editions) on January 31, 2026, providing details about the completion of dispatch and information for obtaining duplicate application forms.